Beyond Monotherapy: The Superior Efficacy of Combined GLP ‐1 Receptor Agonist and SGLT2 Inhibitors on Renal Biomarkers: A Systematic Review and Meta‐Analysis

Documenti analoghi

• SGLT2 Inhibitors and GLP‐1 Receptor Agonists After Acute Kidney Injury: A Systematic Review With Meta‐Analysis
  di: Erin F. Barreto, et al.
  Pubblicazione: (2026)
• Real‐World Cardiovascular Outcomes of GLP ‐1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer
  di: Cyrille K. Cornelio, et al.
  Pubblicazione: (2026)
• Impact of Glucagon‐Like Peptide‐1 Receptor Agonists on Proteinuria in Kidney Transplant Recipients
  di: Stephanie Shabanowitz, et al.
  Pubblicazione: (2026)
• Thromboembolic Risk of Thrombopoietin Receptor Agonists for Adult Primary Immune Thrombocytopenia: A Systematic Review and Meta‐Analysis Integrating Randomized Controlled Trials and Prospective Evidence
  di: Meng‐Fei Dai, et al.
  Pubblicazione: (2025)
• Insulin requirements after switching from GLP ‐1 receptor agonist to dual GIP / GLP ‐1 receptor agonist in patients with type 2 diabetes mellitus
  di: Alexa M. Lahey, et al.
  Pubblicazione: (2025)